The US represents the largest share of the leukapheresis industry, driven by the country's advanced healthcare infrastructure, strong presence of biotechnology and pharmaceutical companies, and growing adoption of cell and gene therapies. The increasing prevalence of hematological malignancies, including leukemia, lymphoma, and multiple myeloma, has significantly increased the demand for leukapheresis procedures across hospitals, cancer centers, and research institutions.

Market Overview

The Leukapheresis Market is projected to reach US$ 133.90 million by 2028 from US$ 74.48 million in 2021; it is estimated to grow at a CAGR of 8.7% from 2021 to 2028. The increasing utilization of leukapheresis in cellular therapy manufacturing, rising prevalence of blood cancers, technological advancements in apheresis systems, and expanding clinical research activities are among the key factors supporting this growth trajectory. The industry is expected to benefit significantly from the continued expansion of personalized medicine and regenerative healthcare solutions over the coming years.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00005515

Technological Advancements Enhancing Procedure Efficiency

Continuous technological innovations in apheresis devices are improving procedural efficiency, patient safety, and treatment outcomes. Modern leukapheresis systems offer enhanced automation, reduced processing times, and improved cell collection accuracy. Manufacturers are introducing advanced software integration, real-time monitoring capabilities, and user-friendly interfaces that streamline workflow management. These developments are encouraging healthcare providers to adopt sophisticated leukapheresis equipment, thereby supporting long-term industry growth.

Growing Investments in Personalized Medicine

The healthcare sector is witnessing a significant shift toward personalized treatment approaches. Personalized medicine relies heavily on patient-specific cellular materials, making leukapheresis an essential component of many therapeutic protocols. As researchers and clinicians continue exploring individualized treatment options for cancer and autoimmune diseases, the demand for efficient cell collection technologies is expected to rise steadily. This trend is creating new growth avenues for healthcare providers, biotechnology companies, and equipment manufacturers operating within the sector.

Expanding Research and Clinical Trial Activities

Research institutions and pharmaceutical companies are increasingly utilizing leukapheresis procedures to support clinical trials and drug development programs. The growing focus on regenerative medicine, immuno-oncology, and stem cell research is generating strong demand for high-quality cellular collection services. Government funding initiatives and private investments in biomedical research are further accelerating innovation and contributing to industry expansion across developed and emerging economies.

North America Leads Global Adoption

North America continues to dominate the industry due to the presence of advanced healthcare infrastructure, leading biotechnology companies, and strong investments in cell therapy research. The region benefits from favorable reimbursement frameworks, increasing adoption of precision medicine, and a high prevalence of hematological malignancies. Additionally, the growing number of FDA-approved cell therapies is encouraging healthcare facilities to expand their leukapheresis capabilities, strengthening regional growth prospects.

Asia Pacific Emerging as a High-Growth Region

The Asia Pacific region is expected to witness substantial growth during the forecast period. Increasing healthcare expenditures, expanding biotechnology sectors, and rising awareness regarding advanced cancer treatments are contributing to regional development. Countries such as China, Japan, South Korea, and India are investing significantly in healthcare infrastructure and biomedical research, creating favorable conditions for the adoption of leukapheresis technologies and services.

Key Players

• Asahi Kasei Corporation
• Fresenius SE & Co. KGaA
• Haemonetics Corporation
• Terumo Corporation
• STEMCELL Technologies Inc.
• HemaCare
• Macopharma
• AllCells
• STEMEXPRESS
• BioIVT

Future Outlook

The future outlook remains highly positive as healthcare providers increasingly adopt advanced therapeutic approaches involving immune cell collection and processing. Growing investments in cell therapy manufacturing infrastructure, rising clinical trial activity, and ongoing technological advancements are expected to support sustained expansion. As personalized medicine becomes more widely adopted across global healthcare systems, leukapheresis will continue to play an indispensable role in enabling next-generation treatment solutions and improving patient outcomes.

Related Reports

Dental Laboratory Workstation Market Growth, Demand & Size by 2034

Dental Silicone Materials Market Size, Demand & Growth by 2034

About Us

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us

Contact Person: Ankit Mathur

E-mail: ankit.mathur@theinsightpartners.com

Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish